Skip to main content

Immune System Diseases

2
Pipeline Programs
10
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Inmunotek
InmunotekSpain - Madrid
2 programs
1
10 HEP/mL Betula verrucosa allergen extractPhase 21 trial
Allergen extractsN/A1 trial
Active Trials
NCT02527122Completed30Est. Aug 2018
NCT02527187Completed201Est. Nov 2016
Biocorp
BiocorpFrance - Issoire
1 program
1
HIB210Phase 11 trial
Active Trials
NCT05928585Completed30Est. Jun 2024
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
CDP7657PHASE_11 trial
CDP7657PHASE_11 trial
Active Trials
NCT01764594Completed24Est. Aug 2014
NCT01093911Completed44Est. Dec 2012
Biogen
BiogenCAMBRIDGE, MA
2 programs
CDP7657PHASE_1
HIB210PHASE_1
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Activation and Function of Eosinophils in Conditions With Blood or Tissue EosinophiliaN/A1 trial
Active Trials
NCT00001406Recruiting800
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Developing Newborn Screening for Infants With Primary ImmunodeficiencyN/A1 trial
Active Trials
NCT00113464Completed100Est. Apr 2007
Genome & Company
Genome & CompanyKorea - Suwon
1 program
Developing Newborn Screening for Infants With Primary ImmunodeficiencyN/A
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
ZostavaxN/A
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
ZostavaxN/A
MSD
MSDIreland - Ballydine
1 program
ZostavaxN/A1 trial
Active Trials
NCT01328548Completed241Est. Mar 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Inmunotek10 HEP/mL Betula verrucosa allergen extract
BiocorpHIB210
UCB PharmaCDP7657
UCB PharmaCDP7657
InmunotekAllergen extracts
MSDZostavax
Human BioSciencesDeveloping Newborn Screening for Infants With Primary Immunodeficiency
Allergy TherapeuticsActivation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Clinical Trials (8)

Total enrollment: 1,470 patients across 8 trials

NCT02527187Inmunotek10 HEP/mL Betula verrucosa allergen extract

Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa

Start: Sep 2015Est. completion: Nov 2016201 patients
Phase 2Completed
NCT05928585BiocorpHIB210

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

Start: Jul 2023Est. completion: Jun 202430 patients
Phase 1Completed
NCT01764594UCB PharmaCDP7657

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Start: Jan 2013Est. completion: Aug 201424 patients
Phase 1Completed
NCT01093911UCB PharmaCDP7657

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Start: Mar 2010Est. completion: Dec 201244 patients
Phase 1Completed
NCT02527122InmunotekAllergen extracts

Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts

Start: Jul 2016Est. completion: Aug 201830 patients
N/ACompleted
NCT01328548MSDZostavax

Zoster Vaccine Response in the Frail Elderly

Start: May 2011Est. completion: Mar 2015241 patients
N/ACompleted
NCT00113464Human BioSciencesDeveloping Newborn Screening for Infants With Primary Immunodeficiency

Developing Newborn Screening for Infants With Primary Immunodeficiency

Start: Jun 2005Est. completion: Apr 2007100 patients
N/ACompleted
NCT00001406Allergy TherapeuticsActivation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Start: Apr 1997800 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,470 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.